{"created":"2023-06-19T08:46:00.160886+00:00","id":1436,"links":{},"metadata":{"_buckets":{"deposit":"94193c52-ddd9-4bca-9929-a38f6b1c5e44"},"_deposit":{"created_by":25,"id":"1436","owners":[25],"pid":{"revision_id":0,"type":"depid","value":"1436"},"status":"published"},"_oai":{"id":"oai:ycu.repo.nii.ac.jp:00001436","sets":["4:71:361:362"]},"author_link":["91","90"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-05-30","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1・2","bibliographicPageEnd":"57","bibliographicPageStart":"47","bibliographicVolumeNumber":"69","bibliographic_titles":[{"bibliographic_title":"横浜医学"},{"bibliographic_title":"Yokohama Medical Journal","bibliographic_titleLang":"en"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"近年，化学療法未施行の進行/局所進行/再発非小細胞肺癌患者を対象としたRCTにおいて全生存期間（overall survival, OS）の代用として無増悪生存期間（progression-free survival, PFS），奏効率（response rate, RR），病勢制御率（disease control ratio, DCR）がしばしば使われている．しかし，これらの指標がOSと相関しているかどうかは十分に検証されていない．私たちは2005年1月1日以降に発表された22709人のNSCLC患者を対象とした44のrandomized controlled trialのデータを用いてsystematic reviewを行い，これを検証した．二群間のhazard ratio（HR），中央値の差（Δ），odds ratio（OR）等の相関係数・決定係数を評価した．HRpfs，ΔPFS，ORrr，およびORdcrはすべて，HRosとの中等度のtrial-levelの関係を有していた．私たちのデータは，ORrrが最善のHRosの代用評価項目であり，HRpfsがそれに次ぐと判断された．PFSとRRが以前の研究から予想されたよりも正確にOSを反映していることを示唆されたが，同時にPFSおよびRRは十分な精度にてOSを予測できないと判断された．今後OSの延長に伴い，PFSはさらにOSを反映しなくなるだろう．\n","subitem_description_type":"Abstract"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"横浜市立大学医学会"}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0372-7726","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"堀田, 信之"},{"creatorName":"ホリタ, ノブユキ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"HORITA, NOBUYUKI","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-07-17"}],"displaytype":"detail","filename":"08_Horita.pdf","filesize":[{"value":"1.7 MB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"横浜医学69巻1・2号（堀田　信之）","url":"https://ycu.repo.nii.ac.jp/record/1436/files/08_Horita.pdf"},"version_id":"6b0c1282-a788-48d1-b519-1fa1124aeb8a"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"無増悪生存期間｜代理エンドポイント｜ 殺細胞性抗癌剤｜分子標的治療","subitem_subject_scheme":"Other"},{"subitem_subject":"Postprogression survival｜Surrogate marker｜Cytotoxic agent｜Molecular targeted therapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"進行/局所進行/再発非小細胞肺癌の一次化学療法の第Ⅲ相ランダム化試験において悪増悪生存期間/奏効率/病勢制御率は全生存期間の代用となるか","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"進行/局所進行/再発非小細胞肺癌の一次化学療法の第Ⅲ相ランダム化試験において悪増悪生存期間/奏効率/病勢制御率は全生存期間の代用となるか"},{"subitem_title":"Progression-free survival, response rate, and disease control rate as predictors of overall survival in phase iii randomized controlled trials evaluating the first-line chemotherapy for non-curable non-small cell lung","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"25","path":["362"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-07-17"},"publish_date":"2018-07-17","publish_status":"0","recid":"1436","relation_version_is_last":true,"title":["進行/局所進行/再発非小細胞肺癌の一次化学療法の第Ⅲ相ランダム化試験において悪増悪生存期間/奏効率/病勢制御率は全生存期間の代用となるか"],"weko_creator_id":"25","weko_shared_id":-1},"updated":"2023-06-19T09:45:31.341557+00:00"}